Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 10.11.2025 2 AJR Am J Roentgenol 1 Am J Surg 9 Ann Surg Oncol 3 BMC Cancer 1 Br J Cancer 2 Breast Cancer 3 Breast Cancer (Dove Med Press) 4 Breast Cancer Res 4 Breast Cancer Res Treat 1 Breast J 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 3 Cancer Res 3 Clin Breast Cancer 3 Clin Cancer Res 1 Eur J Cancer 4 Eur J Surg Oncol 1 Exp Cell Res 1 Gene 2 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Natl Cancer Inst 1 J Surg Oncol 5 N Engl J Med 1 Nat Rev Clin Oncol 1 Nature 1 NPJ Breast Cancer 1 Oncol Rep 1 Oncology 2 PLoS One 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. BERG WA
   Mammography Alone Is Inadequate for Women With Personal History of Breast Cancer.
   AJR Am J Roentgenol. 2025 Nov 5. doi: 10.2214/AJR.25.34143.
   PubMed        
   
   
2. WEAVER OO, Berg WA
   Contrast-Enhanced Mammography-Guided Biopsy: A Step-by-Step Guide.
   AJR Am J Roentgenol. 2025 Jul 2. doi: 10.2214/AJR.25.33038.
   PubMed         Abstract available
   
   

   
   Am J Surg

3. CHEN JH, Yang Z, Yang Z, Meas S, et al
   Primary tumor surgery in patients with de novo stage IV breast cancer: Is there an optimal subgroup for locoregional therapy?
   Am J Surg. 2025;251:116700.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. DE OLIVEIRA-JUNIOR I, Gonzaga MI, Amirati CC, Vilela NM, et al
   Primary Breast Implant-Associated Squamous Cell Carcinoma: A Proposal for a Better Surgical Approach and Clinical Staging System Based on Tumour Characteristics.
   Ann Surg Oncol. 2025;32:9857-9867.
   PubMed         Abstract available
   
   
5. ROSENBERG SM, Rushing C, Schreiber KL, Crowell KA, et al
   Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL Study.
   Ann Surg Oncol. 2025;32:9776-9786.
   PubMed         Abstract available
   
   
6. MA D, Cao H, Wu J, Shang T, et al
   ASO Author Reflections: Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the United States: A Multicenter Real-World Study.
   Ann Surg Oncol. 2025 Nov 6. doi: 10.1245/s10434-025-18643.
   PubMed        
   
   
7. SHEN Y, Gadiraju GK, Gao R, Raymakers AM, et al
   Breast Reconstruction for Inflammatory Breast Cancer: Improving Patient-Reported Outcomes in a High-Risk Population.
   Ann Surg Oncol. 2025 Nov 6. doi: 10.1245/s10434-025-18640.
   PubMed         Abstract available
   
   
8. LEE JA, Lee HS, Jeon S, Kim D, et al
   Risk Factors and Incidence of Reoperation in Direct-to-Implant Breast Reconstruction Surgery Among Patients with Breast Cancer.
   Ann Surg Oncol. 2025 Nov 3. doi: 10.1245/s10434-025-18662.
   PubMed         Abstract available
   
   
9. HANS M, Tamaskar AS, Recko A, Bychkovsky BL, et al
   Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program.
   Ann Surg Oncol. 2025 Nov 1. doi: 10.1245/s10434-025-18656.
   PubMed         Abstract available
   
   
10. ULANER GA, Khan S, Savalia NB, Lopez J, et al
    The Van Nuys DCIS Prognostic Index -->The Silverstein DCIS Prognostic Index.
    Ann Surg Oncol. 2025;32:9475-9477.
    PubMed         Abstract available
    
    
11. JENSEN S, Tvedskov TF, Bechmann T, Tramm T, et al
    Additional Axillary Disease After Neoadjuvant Chemotherapy for Patients with Clinically Node-Negative but Sentinel Node-Positive Disease.
    Ann Surg Oncol. 2025;32:9807-9816.
    PubMed         Abstract available
    
    
12. GWARK S, Hwang YH, Paek SH, Lee YW, et al
    Early Postoperative Outcomes of Tumescent-Free Single-Port Robot-Assisted Nipple-Sparing Mastectomy Compared with Tumescent-Using Technique: A Substudy of Retrospective Multicenter Study (SPROUT, KoREa-BSG 14).
    Ann Surg Oncol. 2025;32:9787-9797.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. IMAMURA S, Mori K, Yasojima H, Mizutani M, et al
    Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer.
    BMC Cancer. 2025;25:1707.
    PubMed         Abstract available
    
    
14. TOKUR O, Aydin S, Kilinc F, Degirmenci T, et al
    Diagnostic value of super microvascular imaging in differentiating axillary lymph nodes: semi-quantitative and qualitative approach in primary breast cancer and suspicious axillary nodes.
    BMC Cancer. 2025;25:1705.
    PubMed         Abstract available
    
    
15. OSHINO T, Shimizu H, Sato M, Nishida M, et al
    Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study.
    BMC Cancer. 2025;25:1718.
    PubMed         Abstract available
    
    

    
    Br J Cancer

16. COCCO P, Bojke C, Hulme C, Hall PS, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis.
    Br J Cancer. 2025 Nov 6. doi: 10.1038/s41416-025-03248.
    PubMed         Abstract available
    
    

    
    Breast Cancer

17. ALTUNDAG K
    Endometrial cancer after breast cancer: caution in interpretation of risk estimates.
    Breast Cancer. 2025 Nov 7. doi: 10.1007/s12282-025-01797.
    PubMed        
    
    
18. LIU J, Ma W, Zhang H, Shi M, et al
    Exploring the prognostic value and biomarker of TEX11 in breast cancer via PANoptosis.
    Breast Cancer. 2025 Nov 3. doi: 10.1007/s12282-025-01794.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

19. CHEN C, Li H, Liu Y, Zhang X, et al
    CLEC3A Promotes Immune Evasion and Tumor Progression by Enhancing PD-L1 Stability to Weaken T Cell Cytotoxicity in Luminal Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:977-995.
    PubMed         Abstract available
    
    
20. PENG LQ, Tang X, Yang GX, Zhu Y, et al
    Accuracy and Influencing Factors of Axillary Lymph Node Ultrasound Assessment After Neoadjuvant Chemotherapy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:967-976.
    PubMed         Abstract available
    
    
21. WEI CW, Cheng MC, Yeh HL
    Stereotactic Accelerated Partial Breast Irradiation Using CyberKnife with Non-Invasive Skin Fiducial Marker Tracking in Early-Stage Breast Cancer: A Retrospective Study of Feasibility, Dosimetry, and Early Outcomes.
    Breast Cancer (Dove Med Press). 2025;17:997-1004.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

22. SHEN J, Guan Y, Boyle J, Fuemmeler BF, et al
    Neighborhood deprivation, breast cancer outcomes and stress-related gene expression in leukocytes and tumor tissue.
    Breast Cancer Res. 2025;27:196.
    PubMed         Abstract available
    
    
23. AZHAR M, Soto F, Su A, Gonzalez NAV, et al
    Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study.
    Breast Cancer Res. 2025;27:197.
    PubMed        
    
    
24. XIE G, Zhang G, Cui J, Zhang Y, et al
    Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer.
    Breast Cancer Res. 2025;27:198.
    PubMed         Abstract available
    
    
25. WANG Y, Ma Y, Liu A, Zhao M, et al
    Longitudinal contrast-enhanced cone beam breast computed tomography for monitoring treatment response in breast cancer neoadjuvant therapy: a comprehensive assessment.
    Breast Cancer Res. 2025;27:199.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

26. PALMQUIST E, Kiernan R, Sevilimedu V, Le T, et al
    Breast surgical site infections in patients undergoing lumpectomy with and without closure of defect.
    Breast Cancer Res Treat. 2025;214:339-346.
    PubMed         Abstract available
    
    
27. WILLERT CB, Mellemkjaer L, Tolver A, Gerdes AA, et al
    Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1/2 carriers: a population-based study with matched controls.
    Breast Cancer Res Treat. 2025;214:355-366.
    PubMed         Abstract available
    
    
28. YANG W, Alongi A, Ma Z, Styblo TM, et al
    Long-term follow-up confirms patients with high-risk breast lesions can be successfully managed at a multidisciplinary conferences.
    Breast Cancer Res Treat. 2025;214:409-418.
    PubMed         Abstract available
    
    
29. HERMANN N, Faermann R, Grinin K, Sklair-Levy M, et al
    Identifying patients most likely to benefit from routine post-operative mammogram after breast-conserving surgery.
    Breast Cancer Res Treat. 2025;214:347-353.
    PubMed         Abstract available
    
    

    
    Breast J

30. WANG J, Zhang D, Huang Q, Fu N, et al
    Clinical Characteristics and Independent Risk Factors for Pathologic Nipple Discharge of 375 Cases.
    Breast J. 2025;2025:6615296.
    PubMed         Abstract available
    
    

    
    Cancer

31. KORIC A, Jiang S, Liu Y, Colditz GA, et al
    Race-related subsequent breast events after ductal carcinoma in situ: A Surveillance, Epidemiology, and End Results-based analysis.
    Cancer. 2025;131:e70164.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

32. NASH SH, Loeffler BT, Verhage E, Sorensen J, et al
    Comorbidities among American Indian and Alaska Native People with Cancer: A Surveillance, Epidemiology, and End Results-Medicare Study.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1914-1923.
    PubMed         Abstract available
    
    

    
    Cancer Lett

33. YANG X, Xia Z
    Commentary: Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
    Cancer Lett. 2025 Oct 30:218108. doi: 10.1016/j.canlet.2025.218108.
    PubMed        
    
    
34. DHRUBA SR, Sahni S, Wang B, Wu D, et al
    Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.
    Cancer Lett. 2025 Oct 30:218101. doi: 10.1016/j.canlet.2025.218101.
    PubMed         Abstract available
    
    

    
    Cancer Res

35. BAUDRE L, Jouault G, Prompsy P, Saichi M, et al
    Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.
    Cancer Res. 2025 Nov 6:OF1-OF16. doi: 10.1158/0008-5472.CAN-25-0995.
    PubMed         Abstract available
    
    
36. BONECHI F, Bacci M, Lorito N, Smiriglia A, et al
    ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer.
    Cancer Res. 2025 Nov 7. doi: 10.1158/0008-5472.CAN-25-1339.
    PubMed         Abstract available
    
    
37. BAUDRE L, Jouault G, Prompsy P, Saichi M, et al
    Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.
    Cancer Res. 2025 Nov 6. doi: 10.1158/0008-5472.CAN-25-0995.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

38. CHAMAN R, Welsh JS, Khatibmasjedi S, Mohammadkhani M, et al
    WITHDRAWN: Editorial for "Real World Safety of Adjuvant Ultra Hypofractionated Radiotherapy in Nonmetastatic Breast Cancer: Acute Cutaneous Toxicity and Esthetic Outcomes".
    Clin Breast Cancer. 2025 Sep 24:S1526-8209(25)00279.
    PubMed         Abstract available
    
    
39. HARRIS N, Aiello P, Detz D, Whiting J, et al
    Non-Wire Bracketed Localization Techniques and Decreased Margin Positive Rates in Breast Cancer.
    Clin Breast Cancer. 2025 Oct 8:S1526-8209(25)00290.
    PubMed         Abstract available
    
    
40. HOIDY WH, Orabiy MO, Essa SM, Jasim LS, et al
    Novel Genetic Susceptibility Markers for Breast Cancer in Iraqi Women: First Evidence of CYP3A4*1B Protective Effects and GSTP1/MTHFR Risk Associations.
    Clin Breast Cancer. 2025 Oct 13:S1526-8209(25)00292.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

41. DAVIS AA, Jaeger E, Hagemann IS, Behdad A, et al
    Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity.
    Clin Cancer Res. 2025;31:4485-4494.
    PubMed         Abstract available
    
    
42. GRAESER M, Gluz O, Schmid P, Jozwiak K, et al
    Multiomic factor analysis for pathologic complete response after pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial.
    Clin Cancer Res. 2025 Nov 3. doi: 10.1158/1078-0432.CCR-25-1923.
    PubMed         Abstract available
    
    
43. LLOYD MR, Weipert CM, Ali A, Solomon SR, et al
    Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer.
    Clin Cancer Res. 2025 Nov 7. doi: 10.1158/1078-0432.CCR-25-3033.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

44. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

45. HANNOUN-LEVI JM, Margenthaler J, Anderson B, Di Micco R, et al
    Local management of second breast cancer event after primary breast conserving therapy: The patient's perspective.
    Eur J Surg Oncol. 2025;51:110484.
    PubMed         Abstract available
    
    
46. LUCOCQ J, Baig H, Michael Dixon J
    The impact of immediate lipofilling on oncological outcomes, complication rates and patient reported outcomes in breast conserving surgery: a systematic review and meta-analysis.
    Eur J Surg Oncol. 2025;51:110446.
    PubMed         Abstract available
    
    
47. REID A, Sibbering L, Burridge I, Kalra L, et al
    Chest wall perforator flaps for partial breast reconstruction: An observational cohort study of 290 women to evaluate clinical and oncological outcomes.
    Eur J Surg Oncol. 2025;51:110430.
    PubMed         Abstract available
    
    
48. KIRWAN CC, Hilton B, Clements K, Dodwell D, et al
    Discrepancy between mammographic and pathological sizing of screen-detected DCIS: Risk factors and impact on ipsilateral recurrence rates.
    Eur J Surg Oncol. 2025;51:110431.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

49. LI J, Zhu X, Feng L, Liu X, et al
    Berberine overcomes paclitaxel resistance in Triple-Negative Breast Cancer by inhibiting HSP90-mediated BRCA1 phosphorylation.
    Exp Cell Res. 2025 Nov 4:114815. doi: 10.1016/j.yexcr.2025.114815.
    PubMed         Abstract available
    
    

    
    Gene

50. GONG F, Liu N, Miao J, Wang C, et al
    Vitamin D regulation of gut microbiota-derived butyrate as a potential inhibitor of breast cancer proliferation.
    Gene. 2025 Nov 4:149872. doi: 10.1016/j.gene.2025.149872.
    PubMed         Abstract available
    
    

    
    Int J Cancer

51. ZENG C, Tan Y, Jiao Z, Hu S, et al
    A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.
    Int J Cancer. 2026;158:172-181.
    PubMed         Abstract available
    
    
52. ANDOUR L, Kroep JR, Putter H, Tollenaar RAEM, et al
    Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study.
    Int J Cancer. 2025 Nov 4. doi: 10.1002/ijc.70219.
    PubMed         Abstract available
    
    

    
    Int J Oncol

53. LI K, Wei L, Huang Y, Wu Y, et al
    [Expression of Concern] Leptin promotes breast cancer cell migration and invasion via IL?18 expression and secretion.
    Int J Oncol. 2026;68:3.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

54. HARISH M DR, Sethi P Dr, Gunaseelan K Dr, Maroju NK Dr, et al
    Effectiveness of low-cost polyurethane film in reducing dermatitis severity in breast cancer patients with higher Fitzpatrick skin types undergoing hypofractionated irradiation with simultaneous integrated boost: An intrapatient randomized controlled
    Int J Radiat Oncol Biol Phys. 2025 Nov 2:S0360-3016(25)06422.
    PubMed         Abstract available
    
    

    
    J Biol Chem

55. SANTJER S, Xu Y, Riethdorf S, Schon G, et al
    The activity of the EMT suppressor GRHL2 is regulated by SUMOylation.
    J Biol Chem. 2025;301:110662.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

56. AIELLO BOWLES EJ, O'Connell K, Bhimani J, Gallagher GB, et al
    Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer.
    J Natl Cancer Inst. 2025 Nov 3:djaf314. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

57. WANG L, Zhou J, Zhao H
    Letter to the Editor: Comment on: "Factors Associated With Residual Positive Lymph Nodes With Targeted Axillary Lymph Node Dissection for Breast Cancer and Accuracy of Clipped Node Retrieval in Non-Mapping Patients".
    J Surg Oncol. 2025 Nov 6. doi: 10.1002/jso.70126.
    PubMed        
    
    

    
    N Engl J Med

58. CAMPONE M
    Vepdegestrant in Advanced Breast Cancer. Reply.
    N Engl J Med. 2025;393:1862.
    PubMed        
    
    
59. KUNKLER IH, Russell NS, Anderson N, Sainsbury R, et al
    Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.
    N Engl J Med. 2025;393:1771-1783.
    PubMed         Abstract available
    
    
60. DE BONIFACE J
    Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer.
    N Engl J Med. 2025;393:1852-1853.
    PubMed        
    
    
61. TROVATO G, Tortora G
    Vepdegestrant in Advanced Breast Cancer.
    N Engl J Med. 2025;393:1861.
    PubMed        
    
    
62. SHIMOI T, Yonemori K
    Vepdegestrant in Advanced Breast Cancer.
    N Engl J Med. 2025;393:1862.
    PubMed        
    
    

    
    Nat Rev Clin Oncol

63. FEHM T, Neubauer H
    Intervening on dormancy to prevent breast cancer recurrence.
    Nat Rev Clin Oncol. 2025 Nov 3. doi: 10.1038/s41571-025-01087.
    PubMed        
    
    

    
    Nature

64. SIMOES BM, Pedley R, McCloskey CW, Roberts M, et al
    Anti-progestin therapy targets hallmarks of breast cancer risk.
    Nature. 2025 Nov 5. doi: 10.1038/s41586-025-09684.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

65. ANAND V, Oderinde B, Siddiqui M, Tyagi A, et al
    Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer.
    NPJ Breast Cancer. 2025;11:120.
    PubMed         Abstract available
    
    

    
    Oncol Rep

66. LI G, Jin B, Zhou J, Fang S, et al
    Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).
    Oncol Rep. 2026;55:11.
    PubMed         Abstract available
    
    

    
    Oncology

67. BANDO H, Sawa A, Bando H, Sato R, et al
    Efficacy and Safety of Mirogabalin Therapy for Paclitaxel-Induced Peripheral Neuropathy (MICHEL Study): A Pilot Study.
    Oncology. 2025;103:985-996.
    PubMed         Abstract available
    
    

    
    PLoS One

68. HASAN MS, Ni S, Kamal FB, Blossey MF, et al
    Sequestration and suppressed synthesis of oncogenic HMGA1 using engineered adenoviruses decreases human pancreatic and breast cancer cell characteristics.
    PLoS One. 2025;20:e0335934.
    PubMed         Abstract available
    
    
69. ZHAO M, Ma Z, Parris AB, Yang X, et al
    LSR overexpression induces chemoresistance in triple negative breast cancer cells through MDR1 upregulation and apoptosis attenuation.
    PLoS One. 2025;20:e0336124.
    PubMed         Abstract available
    
    

    
    Radiology

70. COZZI A, Bellini C, Girometti R, Alcantara Souza R, et al
    Tumor Involvement of the Nipple at Preoperative Contrast-enhanced Mammography: A Multicenter Diagnostic Accuracy Study.
    Radiology. 2025;317:e251350.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.